{"filings":[{"id":899757,"accession_number":"0001437749-26-019779","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-06-08T10:16:04+00:00","items":["1.01","9.01"],"status":"ready","headline":"Catheter Precision invests $1M in Volato Group, receives SOAR and flyExclusive shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchases 2,941,176 SOAR shares at $0.34/share ($1M) in a private placement.","Volato to deliver 451,901 freely tradeable flyExclusive shares valued at ~$1.1M as additional consideration.","Closing subject to customary conditions including no Material Adverse Effect and NYSE American approval.","Registration Rights Agreement requires Volato to file resale registration statement within 10 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":499476,"accession_number":"0001437749-26-017612","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-05-18T20:17:11+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision Q1 revenue up 200% to $432K; net loss cut to $1.7M; Flyte acquisition adds aviation revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $432K (200% YoY) driven by medical device segment (+73%) and new Flyte aviation platform.","Net loss narrowed to $1.7M from $4.0M in Q1 2025; includes ~$560K non-cash charges.","Flyte acquisition generated $200K monthly revenue run rate within 22 days; fleet expanding to 5 jets by end of Q2 2026.","Medical device products in 15 countries; new clinical data on VIVO and LockeT presented at HRS congress.","Company now a dual-engine growth platform combining medical devices and aviation infrastructure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":432000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94941,"accession_number":"0001437749-26-013183","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["3.02","3.03","5.03","9.01"],"status":"ready","headline":"Catheter Precision closes $3.47M Series C-2 preferred; issues $11M Series D for Flyte acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3,470 shares of Series C-2 Preferred at $1,000 stated value sold for gross proceeds of $3,470,000.","11,028 shares of Series D Preferred ($11.03M stated value) issued to SEG Jets and Creatd for Fly Flyte acquisition.","Series C-2 conversion price $0.883/share, floor $0.35; Series D conversion price $1.1038/share, subject to reduction.","Stockholder approval obtained April 15, 2026; proceeds for working capital and general corporate purposes.","Beneficial ownership limitation initially 4.99%, can be increased to 9.99% on 61 days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94940,"accession_number":"0001437749-26-012393","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Catheter Precision shareholders approve reverse split (1:2-1:100) and preferred share issuances","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six proposals passed at April 15 special meeting; 49.5% of outstanding shares voted.","Reverse stock split authorized at ratio between 1-for-2 and 1-for-100, at board's discretion.","Issuance of common stock underlying Series C-1, C-2, C-3, C-4 convertible preferred approved (690,693 for).","Issuance of shares underlying Series D and Series J convertible preferred also approved (~690,600 votes for each).","Approval of conversion price reduction for Series B convertible preferred stock (690,825 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107679,"accession_number":"0001437749-26-010721","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision FY2025 rev +95% to $819K; net loss $17.2M; acquires Flyte aviation platform","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $819K in FY2025, up 95% from $420K in FY2024; gross margin improved to 92.3% from 90.0%.","Net loss of $17.2M in FY2025, of which $7.8M non-cash, compared to $16.6M net loss in FY2024.","Q4 2025 revenue $238K, up 60% YoY; net loss $5.3M ($3.5M non-cash) vs $5.6M in Q4 2024.","Acquired Flyte, a regional air mobility company, post-year-end; financing completed to support two-platform growth strategy.","CE Mark received for LockeT in April 2025; added 32 new customers across VIVO and LockeT platforms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107678,"accession_number":"0001437749-26-007380","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"Catheter Precision acquires 80% of Fly Flyte and Ponderosa Air for $11.6M; raises up to $39M in PIPE","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of 80.02% of Fly Flyte, Inc. and 100% of Ponderosa Air from Creatd for $11.55M in cash and Series D preferred stock.","Private placement of Series C convertible preferred stock raises $1.85M at first close, potential additional raises up to $35.6M.","Proceeds used for restructuring legacy catheter business, potential sale of medical devices, and reducing cash burn.","Conversion prices start at $1.43, adjust to 80% of market with $0.35 floor, subject to stockholder approval.","Registration rights agreement filed to register resale of conversion shares within 30–60 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107677,"accession_number":"0001437749-26-003940","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["1.01","3.02","5.03","7.01","9.01"],"status":"ready","headline":"Catheter Precision secures up to $36.5M institutional financing; converts $9M liabilities into equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO David Jenkins exchanged royalty rights for ~9,490 shares of Series J Preferred Stock convertible into 6,083,005 common shares at $1.56, subject to stockholder approval.","ATM equity offering program terminated; no future equity lines or forward-priced agreements anticipated.","Short-term notes converted to long-term debt with maturities of 2-3 years.","Additional $9M in short and long-term liabilities converted into equity, strengthening balance sheet.","Up to $36.5M in institutional financing secured to expand market presence and advance growth initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107676,"accession_number":"0001437749-26-003387","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"Catheter Precision raises $2.18M in private placement, acquires 19.98% stake in FLYTE for $5.25M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Initial closing of private placement yields $2.18M; additional closings could raise up to ~$44.6M total.","Issues Series C-1 convertible preferred at $1.43/share; conversion price can reset to 80% of market price after stockholder approval.","Acquires 19.98% of Fly Flyte, Inc. (air-mobility) for $5.25M in Series D convertible preferred, contingent on stockholder approval.","Existing Series B preferred and warrants repriced to $1.78, generating $400k cash from warrant exercises.","Proceeds to repay debt, wind down legacy catheter business, and explore going-private or spin-off transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107675,"accession_number":"0001437749-26-000839","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Catheter Precision extends maturity of $1.5M in 8% promissory notes to 2028-2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended $500k note from CEO David A. Jenkins matured Jan 31, 2026, now due Jan 31, 2029.","Extended three FatBoy Capital notes totaling $500k from Jan 31, 2026, to Jan 31, 2029.","Extended Jenkins Family Charitable Institute $500k note from Jan 31, 2026, to Jan 31, 2028.","All notes carry 8% interest; amendments dated Dec 31, 2025, and effective same day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124049,"accession_number":"0001437749-25-036000","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Catheter Precision terminates ATM equity facility after selling ~$4.0M of $4.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated ATM agreement with Ladenburg Thalmann effective November 24, 2025; no penalties.","Prior to termination, $4.0M of common stock sold under the $4.3M capacity.","Remaining $0.3M of at-the-market offering capacity is no longer available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124048,"accession_number":"0001437749-25-035245","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision Q3 revenue up 135% to $226K; net loss down 45% to $2.25M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue Q3 2025: $226K, +135% YoY from $96K; nine-month revenue $581K, +114%.","GAAP net loss Q3 2025: $2.25M, 45% reduction from $4.12M in Q3 2024.","Nine-month net loss $11.4M vs $11.0M; non-cash charges $4.2M.","CE Mark approval for LockeT driving international interest; reorders in South Africa and first French VIVO order.","VIVO clinical studies completed in 2025; CEO expects major US and international expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":581000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124047,"accession_number":"0001437749-25-031036","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders approve increase in authorized shares to 500M for Catheter Precision","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on Oct 10, 2025 had 43.1% quorum (641,616 of 1,487,266 shares outstanding).","Proposal 1: authorized common shares increased from 60M to 500M (497,162 for, 133,882 against).","Proposal 2: WithumSmith+Brown ratified as independent auditor for FY2026 (610,134 for).","Proposal 3: approval to adjourn meeting if needed passed (514,362 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140726,"accession_number":"0001437749-25-027270","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catheter Precision secures UK approval for LockeT; partners with distributor HC21","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["LockeT suture retention device approved for commercialization in the UK; received CE Mark in May 2025.","Exclusive distribution agreement with HC21 (€180M revenue, 500+ employees across UK and Ireland).","LockeT aims to enhance patient comfort, enable earlier discharge, and help NHS reduce waiting lists.","Fatih Ayoglu (Sales Manager EMEA & APAC) highlighted potential to free up hospital capacity and accelerate patient throughput."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140725,"accession_number":"0001437749-25-027153","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Catheter Precision effects 1-for-19 reverse stock split effective August 15, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio of 1-for-19; effective 12:01 a.m. ET on August 15, 2025.","Outstanding shares reduced from ~23,327,516 to ~1,227,764; no change to authorized shares (60M common).","Stock continues trading under symbol VTAK with new CUSIP 74933X 708; no fractional shares issued.","Proportionate adjustments made to per-share exercise prices and shares underlying outstanding options, warrants, and preferred stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140724,"accession_number":"0001437749-25-025935","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision Q2 revenue up 128% YoY to $212K; net loss $5.4M with $3.2M non-cash","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $212K for Q2 2025 vs $93K in Q2 2024, 128% increase; sequential growth 48%.","Net loss $5.4M for Q2 includes $3.2M non-cash charges; cash $838K at June 30.","Received CE Mark for LockeT product; European sales expected to start in Q3 2025.","Completed acquisition of Cardionomic heart failure assets via 82%-owned subsidiary Cardionomix.","Formed Kardionav JV for implant-based software to locate ventricular tachycardia ablation sites."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":355000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140723,"accession_number":"0001437749-25-023654","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Catheter Precision announces 1-for-19 reverse stock split effective August 15, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio of 1-for-19 approved by board after shareholder authorization at July 25 annual meeting.","Pre-split shares reduced from ~23.3M to ~1.2M; no fractional shares issued, cash paid instead.","Split intended to maintain NYSE American minimum bid price requirement; CUSIP changes to 74933X708.","Annual meeting also approved issuance of up to 4.29M shares upon Series L warrant exercise and up to 8.57M shares on Series B preferred conversion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158462,"accession_number":"0001437749-25-020251","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catheter Precision sees record Q2 LockeT sales; Italy distributor secured","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q2 2025 LockeT sales on track to be highest to date, outpacing Q2 2024 by more than $84,000.","Three hospitals — Montefiore, Eisenhower Health, Overland Park Regional — expected to issue >$100K in purchase orders each by end of 2025.","Secured new distributor in Italy; anticipates additional distributors in Spain, Portugal, and UK.","Live case scheduled June 16 with a key opinion leader at an Italian symposium to increase market awareness.","CEO cites expanded existing customer usage and European expansion as drivers of revenue growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158461,"accession_number":"0001437749-25-019768","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catheter Precision Board approves warrant to Ladenburg Thalmann for 257,143 shares at $0.5424","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrant issued to Ladenburg Thalmann as partial compensation for pipe financing closed May 12, 2025.","Exercise requires stockholder approval at annual meeting on July 25, 2025; warrant expires June 6, 2030.","Warrant and underlying shares are unregistered under the Securities Act of 1933."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158460,"accession_number":"0001437749-25-019731","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Catheter Precision terminates Chief Commercial Officer; CEO assumes role temporarily","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Marie-Claude Jacques' employment as CCO discontinued effective June 2, 2025.","CEO David Jenkins will serve as interim CCO until a replacement is hired.","No further details on reason for departure or timeline for search provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158459,"accession_number":"0001437749-25-018985","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Catheter Precision details pro forma dilution to new investors at $1.25/share in ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Historical net tangible book value as of Mar 31, 2025: $(15.8)M or $(1.71)/share; after offering: $(14.6)M or $(0.95)/share.","ATM offering assumes 4,333,333 shares at $0.30/share (May 14 close), net proceeds $1.2M; dilution to new investors $(1.25)/share.","Pro forma adjustments include 1,748,666 shares issued in April 2025; total outstanding after offering ~15.4M shares.","As of Mar 31, 2025, 17.4M warrants (weighted avg exercise $2.20) and 2.2M options outstanding represent additional dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158458,"accession_number":"0001437749-25-017634","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Catheter Precision enters ATM agreement to sell up to $1.3M of common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM agreement with Ladenburg Thalmann allows sale of up to $1.3M of common stock on NYSE American.","Proceeds will be used for operations and working capital; company has no obligation to sell any shares.","Ladenburg receives 3.0% commission on gross proceeds; agreement ends upon sale of all shares or by 5-day notice.","Shares are issued under existing S-3 registration statement (File No. 333-284217) effective Jan 22, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158457,"accession_number":"0001437749-25-017616","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision Q1 revenue up 74% to $143K, net loss $4.0M; cash $450K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $143K vs $82K YoY (+74%); net loss $4.0M including $1.2M non-cash charges.","Cash $450K at March 31; after quarter end secured $1.5M private placement from institutional investors.","Acquired Cardionomics assets via 82%-owned subsidiary Cardionomix, including CPNS system for ADHF.","Acquired PeriKard, LLC (pericardial access kit); first U.S. patent allowed for LockeT device.","Clinical data presented at HRS 2025: VIVO 94% accurate, LockeT safe/effective in 139-patient study."],"consensus_eps_estimate":-3.876,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":143000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158456,"accession_number":"0001437749-25-016188","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["1.01","2.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"Catheter Precision raises $1.5M cash, issues 3,000 Series B Preferred shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Series B Preferred: 3,000 shares at $1,000 stated value; 1,500 sold for $1.5M cash, 1,500 issued for QHSLab notes.","Cash investors: C/M Capital (600 shares, 1.71M warrants), WVP/C/M Capital (400 shares, 1.14M warrants).","Mercer Street receives 2,000 Series B shares and 1.43M warrants in exchange for ~$1.6M defaulted QHSLab notes.","Conversion price $0.35/share; ~2,858 common shares per preferred share; warrants $0.50, 5.5-year term, callable above $1.50 VWAP.","Stockholder approval needed for conversion beyond 19.99% of outstanding and warrant exercise; meeting July 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158455,"accession_number":"0001437749-25-015488","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["1.01","2.03","2.01","3.02","7.01","9.01"],"status":"ready","headline":"Catheter Precision subsidiary acquires Cardionomic's heart failure assets for 1M shares and $1.5M note","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cardionomix purchased CNPS System patents/trademarks for heart failure; closed May 5, 2025.","Consideration: 1M restricted VTAK shares and $1.5M note at 4% due May 2028.","Cardionomix minority stakes: CEO Jenkins (5%), FatBoy Capital (7%), others; requires development financing.","Company seeking additional financing including ATM offering; warns of dilution.","Assets acquired 'AS IS'; Cardionomix has no other significant assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158454,"accession_number":"0001437749-25-012731","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["1.01","2.03","2.01","2.02","8.01","3.02","9.01"],"status":"ready","headline":"Catheter Precision acquires heart failure device assets; Q1 revenue up 73% to $142k","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Subsidiary Cardionomix buys patents/trademarks for Cardionomic's CPNS System (acute decompensated heart failure).","Purchase price: 1M restricted VTAK shares plus a $1.5M promissory note (4% interest, 3-year maturity).","Closing conditions include NYSE American listing approval; deal must close by July 21, 2025.","Preliminary Q1 2025 revenue $142k vs $82k YoY (+73%).","Company warns it needs additional financing to develop assets; dilution expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158453,"accession_number":"0001437749-25-012172","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Catheter Precision subsidiary seeks to buy heart-failure assets from Cardionomic","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Subsidiary Cardionomix would acquire CPNS System assets for 1M restricted VTAK shares and $1.5M promissory note.","Cardionomix is 82% owned by VTAK; CEO David Jenkins holds 5% directly and 7% via FatBoy Capital.","Target closing in first half of Q2 2025; no signed agreement and no guarantee deal will close.","Purchased assets are on 'AS IS' basis; subsidiary will need substantial future financing to develop them.","Cardionomic, Inc. ceased operations; assets assigned for benefit of creditors to Seller LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158452,"accession_number":"0001437749-25-010469","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision FY2024 revenue $420K, net loss $16.6M; Q4 rev $149K up 55% QoQ","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2024 revenue $420 thousand; Q4 2024 revenue $149 thousand, sequential increase of 55% over Q3.","Net loss for 2024 was $16.6 million, of which $7.5 million were non-cash charges; Q4 net loss $5.6 million.","LockeT vascular closure device first sales began Q2 2024 and grew sequentially; 26 institutions evaluated by year-end.","CE Mark for LockeT anticipated Q2 2025 with EU sales expected to start Q3 2025.","New Chief Commercial Officer appointed Q2 2024; majority of sales team replaced and trained by Q3 2024."],"consensus_eps_estimate":-3.876,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":143000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176834,"accession_number":"0001437749-25-007263","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Catheter Precision furnishes March 2025 investor presentation; no details available","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company filed an investor presentation dated March 2025 as Exhibit 99.1.","Presentation content is an image exhibit; no specific financial or operational data extracted.","No material new information can be determined from the furnished exhibit.","Stock continues trading on NYSE American under ticker VTAK."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176833,"accession_number":"0001437749-25-002726","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Catheter Precision awards 700,000 incentive stock options to CEO and CCO at $0.42","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO David Jenkins received options for 450,000 shares; 90,000 vested immediately, 120,000 vest each Jan 2026–2028.","CCO Marie-Claude Jacques received 250,000 options: half time-vesting over 5 years, half performance-vesting based on Q1–Q4 2025 sales targets.","Exercise price $0.42 per share; 10-year term; granted under the 2023 Executive Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176832,"accession_number":"0001437749-25-001385","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-01-17T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Catheter Precision stockholders approve share issuance, authorized share increase, and equity plan expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved issuance of up to 10.7M shares upon exercise of Series K Warrants; 1.4M for, 833K against, 1.9M broker non-votes.","Approved amendment to increase authorized common shares from 30M to 60M; 2.8M for, 1.4M against.","Approved additional 1.5M shares for 2023 Equity Incentive Plan; 1.8M for, 426K against, 1.9M broker non-votes.","Ratified WithumSmith+Brown as auditor for FY2025; 3.7M for, 434K against, 23K abstain.","Legal opinion condition on authorized share increase satisfied; revised opinion filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176831,"accession_number":"0001654954-25-000174","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["3.02","5.02"],"status":"ready","headline":"Catheter Precision appoints Philip Anderson as CFO, grants 500K stock options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Philip Anderson appointed CFO effective Jan 6, 2025, replacing interim CFO Margrit Thomassen who becomes Controller.","Compensation: $200k base salary, discretionary bonus, and option grant of 500,000 shares at $0.53, vesting monthly over 3 years.","Anderson previously CFO at Heritage Distilling, Crown Electrokinetics, Kubient; retired from Nov 2022 to Dec 2024.","Stock options issued under Section 4(a)(2) as inducement to accept employment; no family or discloseable relationships."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193637,"accession_number":"0001654954-24-014464","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision posts Q3 net loss $4.1M, revenue $96K; warrants raise $4.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales revenue for Q3 2024 was ~$96K, net loss $4.1M (including $1.7M non-cash charges); nine-month net loss $11.0M.","Cash at Sept 30 was $1.3M; on Oct 25, 2024, warrant exercise raised gross proceeds of $4.9M.","Company has 87 hospitals in pipeline; 32 institutions in ongoing evaluations; CE Mark for LockeT expected by end of Q1 2025.","Commercial team includes new CCO Marie-Claude Jaques; VIVO procedures ongoing in multiple European countries.","Over 130 patients enrolled in LockeT II comparative study; initial LockeT study published in JCE in August."],"consensus_eps_estimate":-34.884,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":271000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193634,"accession_number":"0001654954-24-013701","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K/A","filed_at":"2024-11-04T23:59:59+00:00","items":["1.01","3.02","3.03","9.01"],"status":"ready","headline":"Catheter Precision reprices seven warrant series to $0.70, expects $3.7M from inducement exercises","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduced exercise price of Series E, F, G, H, I warrants from $1.00/$30/$40 to $0.70 per share on Oct 24, 2024.","Inducement letters for immediate exercise of up to 5.3M warrants; expects ~$3.7M gross proceeds.","Pro forma shares outstanding after exercise: ~10.8M; earlier received $1.185M from 1.185M warrants at original terms.","New Series K warrants issued at $0.70, 200% coverage, 5.5-year term subject to stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193636,"accession_number":"0001654954-24-013502","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Catheter Precision waives beneficial ownership limit for insider warrant holder; 235,000 shares issued for $23.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Waiver granted to Jenkins Family Charitable Institute (trustee is CEO's daughter) to exercise 235,000 pre-funded warrants fully.","Prior 9.99% beneficial ownership cap removed; Institute now holds 6.32% of common stock post-exercise.","Aggregate exercise price paid: $23.50 ($0.0001 per share).","Waiver approved in advance by Company's Board Audit Committee due to related-party nature.","Warrants originally issued in September 2024 underwritten public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193635,"accession_number":"0001654954-24-013313","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["1.01","3.02","3.03","8.01","9.01"],"status":"ready","headline":"Catheter Precision raises $4.9M gross via warrant repricing; issues new Series K warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total gross proceeds of $4.9M, including $3.7M from warrant repricing and $1.185M from prior exercises.","Exercise price reduced from $1.00/$30/$40 to $0.70 per share for Series E, F, G, H, I warrants.","New Series K warrants issued for 200% of exercised shares, $0.70 exercise price, 5.5-year term, exercisable only after shareholder approval.","Pro forma shares outstanding approximately 10.8 million after warrant exercises.","Ladenburg Thalmann served as exclusive warrant inducement agent with an 8% cash fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209957,"accession_number":"0001654954-24-011589","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Catheter Precision closes $3.6M public offering with warrants; net proceeds ~$2.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering comprised of 805,900 common units at $1.00/unit and 2,773,000 pre-funded units at $0.9999/unit.","Each unit includes a share (or pre-funded warrant at $0.0001), Series H, I, and J warrants all exercisable at $1.00.","Underwriters partially exercised overallotment, adding 458,623 common stock units to the offering.","Estimated net proceeds to company after discounts and expenses are approximately $2.6 million.","Post-closing shares outstanding were 2,656,652; by Sep 5, 2024, reached 2,804,152 on further warrant exercises."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209956,"accession_number":"0001654954-24-011150","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-08-27T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Catheter Precision amends $1.5M promissory notes: maturity to Jan 2026, rate to 12%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended maturity of five 8% short-term notes from Aug 30, 2024 to Jan 31, 2026.","Interest rate raised from 8% to 12% effective Aug 31, 2024; interest through Aug 30 due.","Notes total $1.5M: $500k from CEO David Jenkins, $500k from Jenkins Trust, $500k from FatBoy Capital.","All holders are related parties: CEO, his family trust, and an affiliate he controls.","Amendments reflect near-term liquidity need; higher cost and extended debt terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209955,"accession_number":"0001654954-24-010758","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision Q2 revenue $93K, net loss $4.2M; cash only $16K at June 30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $93K, H1 $175K; net loss Q2 $4.2M, H1 $6.9M.","Cash at June 30 just $16K; rose to $330K by Aug 12 but remains extremely low.","First commercial LockeT sales in US: $38K in both Q2 and H1; 23 hospitals scheduling evaluations.","Total assets $26M, shareholders' equity $14.3M as of June 30.","14 new sales/clinical hires; VIVO evaluation started in Italy; VIVO EU Registry completed in June."],"consensus_eps_estimate":-50.9694,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":175000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209954,"accession_number":"0001654954-24-009649","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Catheter Precision borrows $500K from CEO-related trust at 8%, due Aug 30, 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Jenkins Family Charitable Institute (CEO David A. Jenkins is settlor, his daughter is trustee) lends $500K via 8% promissory note maturing Aug 30, 2024.","This brings total related-party short-term notes (Jenkins/FatBoy Capital) to $1.5M, all due Aug 30, 2024.","Note is unsecured, contains standard events of default; proceeds used for general corporate purposes.","CEO Jenkins and affiliates hold over 10% of common stock, convertible preferred, options, and royalty rights on LockeT device sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209953,"accession_number":"0001654954-24-009421","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Catheter Precision converts all Series A Preferred; no shares remain outstanding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On July 23, 2024, 400 Series A Preferred shares converted into 25,000 common shares.","Following conversion, no Series A Preferred shares remain outstanding.","Common shares issued under Section 3(a)(9) exemption and registered on Form S-1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209952,"accession_number":"0001654954-24-009309","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Catheter Precision gets $100K CEO loan at 8% due Aug 30, 2024, adding to prior $900K","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entity controlled by CEO David Jenkins loans $100,000 via 8% promissory note due August 30, 2024.","Note issued to FatBoy Capital LP, which is controlled by Jenkins; he owns >10% of common stock.","This loan adds to $500K (May 2024) and $400K (June/July 2024) in prior related-party loans, totaling $1M.","Repayment expected from proceeds of pending S-1 registration statement securities sale.","Note includes customary default provisions; interest accrues at 8% per annum on 30/360 basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209951,"accession_number":"0001654954-24-008907","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Catheter Precision files 1-for-10 reverse stock split; effective July 15, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio of 1-for-10; shares outstanding reduce from ~9.0M to ~901k.","Authorized common stock reduced from 300M to 30M shares concurrently.","No fractional shares issued; cash paid for fractional interests; CUSIP changes to 74933X 609.","Proportionate adjustments to stock options, warrants, and preferred stock conversion terms.","Stock symbol remains VTAK; trading on NYSE American on split-adjusted basis from July 15."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209950,"accession_number":"0001654954-24-008787","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Catheter Precision shareholders approve reverse stock split, authorize share decrease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["James Caruso and Andrew Arno elected as Class III directors with ~2.6M votes each.","Amendment to reduce authorized common stock approved by ~4.07M votes.","Reverse stock split (1:5 to 1:15) authorized by ~3.99M votes.","2M additional shares for 2023 Equity Incentive Plan approved by ~2.36M votes.","Nonbinding vote on executive compensation set to every three years based on shareholder preference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209949,"accession_number":"0001654954-24-008613","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["2.02","3.02","8.01","9.01"],"status":"ready","headline":"Catheter Precision reports Q2 revenue of $94,840; approves 1-for-10 reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q2 2024 revenue $94,840, including first LockeT sales ($40,500) and VIVO ($54,340).","Six-month 2024 revenue $176,923; 15% sequential quarter-over-quarter growth.","Board approved 1-for-10 reverse stock split effective July 15, 2024; shares reduce from 8.4M to ~839K.","Series A Preferred conversion issued 814,228 common shares on July 1, 2024.","New CCO Marie Claude Jaques hired in May; sales pipeline growing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209948,"accession_number":"0001654954-24-008484","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Catheter Precision receives $250K 8% note from CEO entity due Aug 30, 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entity controlled by CEO David A. Jenkins loans $250K at 8% interest, maturing August 30, 2024.","Note adds to $500K loan in May 2024 and $150K loan in June 2024 from same source.","Proceeds from S-1 securities sale expected to repay the note.","Jenkins and affiliates hold >10% common stock, convertible preferred, stock options, and 11.77% royalty on LockeT sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228145,"accession_number":"0001654954-24-008238","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Catheter Precision secures $150K 8% short-term note from CEO's entity due Aug 30, 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["CEO David A. Jenkins' entity FatBoy Capital LP loans $150,000 at 8% interest, maturing August 30, 2024.","Loan is in addition to $500,000 loaned by Jenkins in May 2024; repayment expected from S-1 securities proceeds.","Note accelerates on customary defaults; Jenkins holds >10% common stock, convertible preferred shares, and 11.77% royalty rights.","Missiaen Huck, CEO's daughter, serves as non-executive COO; related-party details in proxy filed May 16, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228144,"accession_number":"0001654954-24-007260","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"CEO loans Catheter Precision $500K at 8%; enters royalty agreement for LockeT device","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["CEO David Jenkins loaned $500,000 via 8% promissory note due August 30, 2024.","Royalty agreement with co-inventor Auston Locke: 5% net sales of LockeT device until $1M, then 2% up to $10M; ends Dec 31, 2033 or patent expiry.","Jenkins and affiliates hold >10% common stock, Series X preferred convertible into >8M shares, and 11.77% royalty on LockeT sales.","Missiaen Huck, Jenkins' adult daughter, serves as non-executive COO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228143,"accession_number":"0001654954-24-006741","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director John P. Francis will not stand for reelection at July 3, 2024 Annual Meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John P. Francis informed Board he will not stand for reelection at the 2024 Annual Meeting on July 3, 2024.","Mr. Francis' term as director will expire at the Annual Meeting.","No disagreement exists between Mr. Francis and the Company regarding operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228142,"accession_number":"0001654954-24-005695","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision Q1 2024 revenue $82K, net loss $2.7M; cash drops to $0.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue of $82,000; net loss of $2.7 million.","Cash decreased from $1.5M (Mar 31) to $0.5M (May 6, 2024).","LockeT submitted for CE Mark approval, expected Q3 2024; initial clinical data positive.","Appointed Marie-Claude Jaques as Chief Commercial Officer effective May 1, 2024.","Company is seeking additional financing to pursue business objectives."],"consensus_eps_estimate":-80.6208,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":82000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228141,"accession_number":"0001654954-24-004187","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catheter Precision files revised auditor consent correcting registration statement references","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Original consent in 2023 10-K mistakenly referenced Form S-3 333-269491 and Amendment No.1 333-270919.","Revised consent filed April 2, 2024 corrects references to Post-Effective Amendment No.1 to Form S-3 on Form S-1.","No financial results or other disclosures in the 10-K are affected by the correction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":2220000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-04-03T23:59:59+00:00|228141"}